We fractionated frontal cortical grey matter from human Alzheimer's disease and control subjects into four biochemically defined pools that represent four distinct compartments: soluble/cytosolic, peripheral membrane/vesicular cargo, integral lipid/membranous pools and aggregated/insoluble debris. Most of the readily extractable amyloid-b remains associated with a lipid/membranous compartment. There is an exchange of amyloid-b between the biochemical pools that was lost for the amyloid-b 42 species in Alzheimer's disease, consistent with the peptide being irreversibly trapped in extracellular deposits. The quantitative amyloid-b data, combined with magnetic resonance imaging volumetric analysis of the amount of cortical grey matter in brain, allowed us to estimate the total mass of amyloid-b in Alzheimer's disease (6.5 mg) and control (1.7 mg) brains. The threshold positron emission tomography standard uptake value ratio of 1.4 equates to 5.0 kg amyloid-b/g of grey matter and the mean Alzheimer's disease dementia standard uptake value ratio level of 2.3 equates to 11.20 kg amyloid-b/g of grey matter. It takes 19 years to accumulate amyloid from the threshold positron emission tomography standard uptake value ratio to the mean value observed for Alzheimer's disease dementia. This accumulation time window combined with the difference of 4.8 mg of amyloid-b between Alzheimer's disease and control brain allows for a first approximation of amyloid-b accumulation of 28 ng/h. This equates to an estimated 2-5% of the total amyloid-b production being deposited as insoluble plaques. Understanding these rates of amyloid-b accumulation allows for a more quantitative approach in targeting the failure of amyloid-b clearance in sporadic Alzheimer's disease.
Introduction
Future development of disease-modifying therapies specifically targeting amyloid-b requires a more detailed understanding of the following questions: how much amyloid-b is in the Alzheimer's disease brain; where is it located; what species of amyloid-b does molecular imaging with Pittsburgh compound B (PiB)-like PET ligands display; what are the estimated rates of accumulation of amyloidb over the 30 year natural history of Alzheimer's disease; and which biochemical pools of amyloid-b are most altered in Alzheimer's disease?
Amyloid-b biogenesis begins with proteolytic cleavage from an integral transmembrane domain of the amyloid protein precursor (APP) (Kang et al., 1987) . After cleavage, it is commonly assumed that amyloid-b transitions directly to a soluble form (Haass and Selkoe, 1993) , which then follows assembly pathways towards toxic soluble/diffusible oligomers (amyloid-b o ) or relatively inert fibrillary amyloid polymers within the extracellular interstitial compartments as plaques and perivascular deposits (Lambert et al., 1998; McLean et al., 1999) .
The process of release of amyloid-b from the membrane, although logical, is not supported by evidence that amyloid-b is released directly into a soluble phase. The process of transition from the membrane would require a significant amount of energy and specialized chaperones to overcome the ordering of water molecules around the hydrophobic C-terminus of amyloid-b. Amyloid-b has not been shown to be actively transported from the membrane. On the contrary, biophysical investigations of amyloid-b and membranes indicate that amyloid-b is stable and well incorporated into artificial membranes (Phan et al., 2013) . When membranes are made in the presence of amyloid-b, the peptide fails to spontaneously transition from the membrane into the soluble phase. The natural tendency of amyloid-b to remain associated with the membrane or hydrophobic environment has significant implications for our understanding of the assembly amyloid-b o and amyloid-b fibrils in the Alzheimer's disease brain.
To examine the membrane pools in which amyloid-b is distributed, we used a sequential extraction protocol to biochemically fractionate amyloid-b into cytosolic (Tris-buffered saline), peripheral membrane/vesicular (Na 2 CO 3 ), integral lipid/membrane (urea/detergent) and fully polymerized fibrillar (formic acid) extractable pools from post-mortem Alzheimer's disease and control brains. We determined the total amyloid-b present in Alzheimer's disease and age-matched control brains, the distribution of amyloid-b between these biochemical pools, and their correlations with PET-amyloid values obtained before death. From these data we can estimate which biochemical pools are most affected in Alzheimer's disease and derive a first approximation of the rates of brain tissue amyloid-b accumulation.
Materials and methods

Brain tissue
Two cohorts of post-mortem frontal cortex samples were obtained from the Victorian Brain Bank Network (see Supplementary Table 1 for demographics). The first cohort was age-matched healthy control brain (n = 27), defined as free from Alzheimer's disease lesions in as much as the numbers of plaques and tangles were well below the cut-off values for a neuropathologic diagnosis of Alzheimer's disease (NIA Reagan criteria). No other major neurological disease was present. Alzheimer's disease brains (n = 30) met the standard criteria for Alzheimer's disease neuropathologic diagnosis. The second cohort of frontal cortex tissue was obtained from ante-mortem amyloid-b amyloid PET imaged subjects (Supplementary Table 1 ) that had been imaged as part of the Australian Imaging, Biomarker and Lifestyle study (Ellis et al., 2009 ) and a registration study of florbetaben (Sabri et al., 2015) .
Tissue fractionation
Hemisected frozen brains at À80 C were thawed to À20 C and 1 cm slices of frontal cortex taken. The meninges were removed and grey matter was dissected into 0.2-0.5 g aliquots from $5 g sections of frontal cortex. Care was taken to keep the tissue frozen during the dissection process. The tissue was weighed, thawed on ice, and homogenized using a BioMasher (Omni International). Tissue was placed in the BioMasher, the plunger was inserted, and then the apparatus was centrifuged at 14 000g with a desktop centrifuge. After centrifugation Trisbuffered saline (TBS, 50 mM Tris pH 8.0, 100 mM NaCl) containing EDTA-free protease inhibitors (Roche) was added at a ratio of 1:4 (tissue:buffer, w/v) ( Supplementary Fig. 1 ).
TBS fraction
The homogenized sample was then transferred to ultracentrifuge tubes and centrifuged at 100 000g for 30 min at 4 C. The supernatant containing the soluble material was collected as the TBS fraction.
Na 2 CO 3 fraction
The resulting pellet was resuspended in 100 mM Na 2 CO 3 pH 11.0 (1:4, tissue:buffer) by triturating 10-15 times with a 1 ml pipette. Samples were left to incubate 20 min on ice before centrifugation at 100 000g for 30 min at 4 C. The supernatant containing peripheral membrane proteins and vesicular material was recovered as the Na 2 CO 3 fraction.
Urea/detergent fraction
The remaining pellet was re-suspended with 7 M urea, 2M thiourea, 4% CHAPS, 30 mM bicine, pH 8.5 and centrifuged as before. The supernatant was retained as the urea/detergent fraction. formic acid fraction. All the above fractions were stored at À80 C until analysis.
Western blot analysis
For the TBS and Na 2 CO 3 fractions, 25 ml was mixed with 5 ml of 4Â Laemmli loading buffer with Orange G substituted for bromophenol blue. The samples were then heated at 70 C for 10 min followed by bath sonication for 5 min, centrifuged at 14 000g, on a desktop centrifuge before being loaded on a 4-12% Bis-Tris precast gel (Invitrogen). The gel was transferred using the iBlot Õ system following the manufacturer's instructions (Program P5, 7 min). After transfer to 0.2 mm nitrocellulose the amyloid-b epitope was exposed by boiling the membrane in phosphate-buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , pH 7.4) for 5 min in a 1200 W microwave at 50% of maximum power.
The blot was blocked with 0.5% non-fat dry milk for 1 h at room temperature and then probed overnight at 4 C with 6E10 (1 mg/ml). The blot was then washed five times for 5 min each with TBST (10 mM TRIS, pH 8.0, 150 mM NaCl, 0.1% Tween 20) and then probed with anti-mouse-HRP (Dako, P0260) followed by an additional round of washing with TBST (5 Â 5 min). The blot was developed with Millipore ECL (Immobilon western Chemilum HRP substrate, WBKLS0500) and images were captured with Fujifilm LAS-3000. For the TBS and Na 2 CO 3 western blot the amyloid-b standards used were 0.3, 1, 2 ng. The same process was repeated for the urea/detergent and formic acid fractions except that the urea/detergent fraction was diluted 1:10 (v/v) in 1 Â loading buffer and the formic acid fraction was diluted 1:20 into PBS pH 7.4. The equivalent of 2 ml of neat material was loaded on the gel with amyloid-b standards and 3, 10, 30 ng for the urea/detergent and formic acid fractions.
Amyloid-b ELISA
Concentration of amyloid-b 40 , 42, n-40 and n-42 were determined following the manufacturer's protocols (Innogenetics, INNO-Bia-xMAP). Each fraction was prepared for ELISA as follows: TBS and Na 2 CO 3 fractions were diluted 1:1 with dilution buffer, urea/detergent fractions were diluted 1:70, and the formic acid fractions were neutralized and diluted 1: 200 with 1 M Tris base.
Immunoprecipitation and mass spectrometry
Immunoprecipitation was conducted using Protein G Dynabeads TM (ThermoFisher Scientific). The amyloid-b antibodies used were a mixture of WO2 (epitope residues 2-8) and 4G8 (epitpope residues 17-24). Each fraction was prepared differently for immunoprecipitation. The urea/detergent fraction (50 ml) was diluted with 950 ml PBS and then incubated with the antibody-bound Dynabeads TM for 2 h at room temperature. After incubation the beads were washed three times with 500 ml PBS and twice with 200 ml water (18 M). Samples were eluted from the beads with 25 ml of 2% ammonium hydroxide, and lyophilized to dryness. The dried samples were resuspended with 5 ml 8% formic acid (v/v) in 8% acetonitrile (v/v) and sonicated for 5 min. To a steel MALDI (matrix-assisted laser desorption ionization) plate, a seed layer of 0.5 ml of 1 mg/ml alpha-cyano-4-hydroxycinnaminc acid (CHCA) in 100% acetonitrile was deposited and allowed to dry. This was followed by 2 ml of the sample. Finally, the matrix layer of 10 mg/ml CHCA in 30% acetonitrile containing 0.1% trifluoroacetic acid was plated over the sample (0.2 ml). MALDI spectra were collected in reflector mode on an Ultraflextreme III (Bruker).
Amyloid-b imaging analysis
Amyloid-b imaging was performed with two different radiotracers:
11 C-PiB (PiB) and 18 F-florbetaben (FBB). Overall, five participants underwent PiB and seven underwent FBB. The PET methodology for each tracer has been previously described in detail (Villemagne et al., 2011) . Briefly, a 30-min acquisition was started 40 min post-injection of PiB, and 90 min post-injection of FBB. A transmission scan was performed for attenuation correction. PET images were reconstructed using a 3D RAMLA algorithm. For semiquantitative analysis, a volume of interest template was applied to the summed and spatially normalized PET images to obtain standardized uptake values. The PiB and FBB images were then scaled to the standardized uptake values of the cerebellar cortex, used as reference region to generate a tissue ratio termed SUVR. A local measure of amyloid-b burden was computed using the mean SUVR in the left and right dorsolateral prefrontal cortices. To combine and use all the continuous SUVR data from both tracers, the FBB scans were transformed into BeCKeTs, a PiB-like SUVR linear transformation that allows comparison of SUVR across tracers (Villemagne et al., 2014) .
MRI
AIBL participants (310 controls and 49 Alzheimer's disease patients) underwent a 3 T MRI using the 3D magnetization prepared rapid gradient echo (MPRAGE) sequence, with 1 Â 1 mm in-plane resolution and 1.2 mm slice thickness, repetition time/echo time/inversion time = 2300/2.98/900, flip angle 9 and field of view 240 Â 256 and 160 slices. T 2 fast spin echo and fluid-attenuated inversion recovery (FLAIR) sequences were also obtained. Magnetic resonance images were spatially normalized to the Montreal Neurological Institute (MNI) single-subject MRI brain template, using MilxView Õ (http://research.ict.csiro.au/software/milxview). As described elsewhere, T 1 magnetic resonance images for each subject were classified into grey matter, white matter and CSF using an implementation of the expectation maximization segmentation algorithm (Bourgeat et al., 2010) . Cortical grey matter volumes (expressed in g) were normalized for head size using the total intracranial volume, defined as the sum of grey matter, white matter and CSF. The corresponding average [ AE standard deviation (SD)] cortical grey matter volumes for controls and Alzheimer's disease patients were 527.4 AE 26.8 g and 496.7 AE 30 g, respectively.
Statistical analyses
Sample demographic characteristics were assessed using the independent samples t-test (age and post-mortem interval) and the chi-square test (gender and APOE "4 allele status).
To determine statistical significance for comparisons between biomarkers measured from healthy control and Alzheimer's disease brain tissue samples, the independent sample t-test was used, while Pearson's correlation was used to assess correlation of biomarkers between cell fractions. Statistical significance was considered post-Bonferroni correction for four biomarkers, over four cell fractions (corrected P-value = 0.05/ 16 = 0.003).
Results
Definition of the biochemical pools of amyloid-b
Significant effort has been directed to understand the soluble oligomeric forms of amyloid-b, however, the pathway describing how amyloid-b transitions to the soluble phase from the membrane after cleavage from the amyloid precursor protein has not been clearly established. We used a series of sequential biochemical extractions to ask how amyloid-b was distributed in human frontal cortex ( Supplementary Fig. 1 ). Each of these pools approximates a different biochemical or cellular location. The TBS fraction consists of cytosolic and extracellular soluble proteins, and the canonical soluble amyloid-b species. The resulting pellets from the TBS fractions were then extracted with alkali Na 2 CO 3 (pH11), which extracts proteins peripherally associated with the membrane and collapses vesicular bodies releasing their cargo (Fujiki et al., 1982) . The urea/detergent fraction is a classical extraction procedure for integral membrane proteins (Rabilloud et al., 1997) . The pellets that remain after extraction with urea/detergent often had a yellow/brow colour, most likely due to the presence of lipofuscin. These pellets were then dissolved with 80% formic acid, which extracted any additional membrane proteins, and fibrillar amyloid deposits or cellular debris (Masters et al., 1985; Zhao et al., 2013) .
Quantitation of amyloid-b
We used western blot and ELISA to determine the amount of amyloid-b present in each of the biochemical fractions from 27 control brains and 30 pathologically confirmed cases of Alzheimer's disease using NIA Reagan criteria (Table 1) . Quantitation of amyloid-b via western blot demonstrated that only 0.2% of total amyloid-b in Alzheimer's disease brain is contained in the TBS fraction, with 6.6%, 47.7% and 45.4% of amyloid-b in the Na 2 CO 3 , urea/detergent and formic acid fractions, respectively (Supplementary Table 2 ). In contrast, control tissue has a percentage distribution of 0.28% TBS, 3.5% Na 2 CO 3 , 65.2% urea/detergent and 31.0% formic acid fractions. Quantitation of the total amyloid-b 1-40 and amyloid-b 1-42 in each fraction by ELISA yielded a per cent distribution of amyloid-b in Alzheimer's disease, similar to that observed by western blot, with 0.03%, 0.24%, 56.7% and 42.2% of extracted amyloid-b 40 + 42 in the TBS, Na 2 CO 3 , urea/detergent and formic acid fractions, respectively. The distribution of amyloid-b between fractions for control brain tissue measured by ELISA was similar to that found by western blot (TBS 0.04%, Na 2 CO 3 0.32%, urea/detergent 68.4%, and formic acid 31.25%).
We next asked how the abundance of amyloid-b in each fraction compared between Alzheimer's disease and control tissue. As expected, we found a significant elevation in the amount of amyloid-b in each fraction from Alzheimer's disease tissue (Fig. 1B) . However, the elevation between fractions was not uniform. We found that the largest change in amyloid-b levels compared to control tissues was a 7.7-fold increase in the Na 2 CO 3 fraction (Supplementary Table 2 ). The levels of amyloid-b in both the TBS, and urea/detergent fractions were elevated three times compared to control (Supplementary Table 2) , which is consistent with previous reports (McLean et al., 1999) . In the formic acid fraction, the increase in amyloid-b was 5.9-fold above control levels.
Measurement of amyloid-b 1-42 and amyloid-b n-42 with ELISA demonstrated a significant elevation between Alzheimer's disease and controls in each fraction (Fig. 1C-F) . Similarly, amyloid-b 1-40 was elevated in all of the biochemical fractions, although this did not reach statistical significance within the urea/detergent or formic acid fractions ( Fig. 1E and F) . The level of amyloid-b n-40 was significantly elevated in all fractions except the urea/ detergent fraction ( Fig. 1E , P = 0.007, Bonferroni correction P = 0.003).
Amyloid-b 42 species dominate the human brain profile. There are over 30 different species of amyloid-b that have been described from brain (Sergeant et al., 2003; Portelius et al., 2010) . We used a combination of western blot, ELISA and mass spectrometry-based techniques to determine the species of amyloid-b in each of the four biochemical fractions from human brain tissue.
The analysis using ELISA demonstrated that amyloid-b 1-42 and amyloid-b n-42 were the most abundant species in all of the biochemical fractions for both control and Alzheimer's disease tissue. (Fig. 1C-F) . To confirm the dominant abundance of amyloid-b 42 species shown by ELISA, we used urea SDS-PAGE western blot, which resolves species of amyloid-b based on differences in the hydrophobicity of amyloid-b peptides (Klafki et al., 1996; McColl et al., 2012) . This technique reveals that amyloid-b from human brain predominantly ended in residue 42 with amyloid-b 4-42 (Fig.  2) . To gain a greater characterization of amyloid-b peptides, we used MALDI mass spectrometry analysis of amyloid-b peptides immunoprecipitated with a mixture of WO2 (epitope region 4-8) and 4G8 (epitope region 17-24). Analysis of the membrane and formic acid fractions demonstrated an array of N-terminally truncated 42 species (Fig. 2B and C) . A similar array of amyloid-b species was observed for the Na 2 CO 3 fraction (data not shown). The TBS fraction was not analysed due to low abundance.
Ratio of amyloid-b 42/40 species
In Alzheimer's disease, the ratio of amyloid-b 42/40 has been reported to be decreased in plasma (Rembach et al., 2014a, b) CSF, (Shoji et al., 1998; Jensen et al., 1999; Lleo et al., 2015) and brain (Näslund et al., 1994) . We compared the ratio of amyloid-b 42/40 and N-terminally truncated forms amyloid-b n-42/ n-40 in each of the biochemical fractions (Fig. 3) . Contrary to previous reports, the ratio of amyloid-b 42/40 was increased in the TBS fractions (Fig. 3D) . The N-terminally truncated amyloid-b n-42/n-40 ratio was elevated in all fractions but not significantly after correction for false discovery ( Fig. 3A and C) .
Total levels of amyloid-b in human brain
Determining the amount of amyloid-b that accumulates in an Alzheimer's disease brain has potential implications for therapeutic dosing and modelling the turnover rates of amyloid-b. The current extraction procedure allows for a nearly complete extraction of amyloid-b from human brain tissue. Using the amount of cortical grey matter in a normal (527.4 AE 26.8 g, mean AE SD) or Alzheimer's disease brain (496.7 AE 30 g, mean AE SD), as determined by MRI, we estimated and then compared the total amount of amyloid-b in Alzheimer's disease and control brains (Table 1) . In Alzheimer's disease brain there was an average total of 6.5 AE 5.0 mg amyloid-b compared to control brain 1.7 AE 2.3 mg. These values are within the range of previous estimations (Nä slund et al., 2000; Karran et al., 2011; Cohen et al., 2013) . Using the time frame of amyloid-b accumulation of 19.2 years from threshold to onset of dementia and given a constant rate of change, this yields a rate of amyloid-b accumulation of 28 AE 27 ng/h (Table 2) . Because the control samples in this cohort are still relatively old, we sampled a small cohort with an average age of 53.7 years (range 16-67 years, Supplementary Table 4) that is slightly younger than the control group for this study (average age of 77 years). The purpose of this was a preliminary investigation to the levels of amyloid-b at an earlier point in the human lifespan. The younger group and particularly the single subject at 16 years of age, demonstrated $3-10 times lower levels of amyloid-b per gram of brain ( Supplementary Fig. 2 ). Thus, a first approximation of the rate of amyloid-b accumulation lies in the order of 2-100 ng/h.
Correlation between different fractions
We observed significant correlations between the levels of 1-40, n-40, 1-42 and n-42 in control tissue between the TBS, Na 2 CO 3 , urea/detergent and formic acid fractions (Supplementary Table 3 ). In the control samples, the levels of amyloid-b 1-42 and amyloid-b n-42 of TBS fraction correlated with the Na 2 CO 3 fraction levels and between the Na 2 CO 3 and urea/detergent fractions, and between the urea/detergent and the formic acid fractions (Fig. 4A -C and G-I). However, these correlations are notably lost for amyloid-b 42 species in Alzheimer's disease tissue samples ( Fig. 4D -F, J-L and Supplementary Table 3 ).
The amyloid-b urea/detergent and formic acid fractions correlate best with PET-SUVR
To determine if PET tracers reflect a level of a particular pool of amyloid-b, we conducted the fractionation using tissue from 12 individuals who had ante-mortem amyloidb-PET scans (mean interval between PET scan and death 18.6 AE 14.3 months, Supplementary Table 1) , and determined the level of amyloid-b by western blot analysis. We observed that amyloid-b-PET-SUVR correlated best with the formic acid and urea/detergent pools of amyloidb ( Fig. 5C and D) . To a lesser extent, the level of brain amyloid-b amyloid correlated with the Na 2 CO 3 fraction (Fig. 5B ). There was no correlation between the TBS fraction levels of amyloid-b and PET-SUVR (Fig. 5A ). When the total amount of amyloid-b was determined, by summing the amyloid-b from each fraction, we found a strong positive correlation indicating that every 0.1-unit increase in amyloid-b-PET-SUVR equals 0.7 mg more amyloid-b per gram of grey matter (Fig. 5E ). The threshold PET-SUVR of 1.4 equates to 5.0 mg of amyloid-b per gram of grey matter and the mean Alzheimer's disease dementia level of 2.3 equates to 11.2 mg/g of grey matter (Fig. 5E ).
Discussion Distribution of amyloid-b
In general, our knowledge about the neurotoxicity of amyloid-b is based on the measurement and experimentation with soluble and oligomeric forms of amyloid-b (amyloidb o ) peptides. Thus it is important to understand how amyloid-b transitions from the membrane after cleavage through to a soluble or diffusible version. To address this, we used a sequential extraction procedure that generates four biochemically distinct pools of proteins: (i) TBS soluble fraction composed of cytosolic and extracellular soluble proteins; (ii) Na 2 CO 3 fraction that captures peripheral membrane and vesicular proteins; (iii) urea/detergent fraction that consists of integral membrane proteins; and (iv) formic acid fraction that extracts recalcitrant membrane proteins and solubilizes fibrillar amyloid and other debris. Measurement of amyloid-b in these four distinct biochemical pools revealed that less than 0.2% of the extractable amyloid-b was in the TBS soluble phase, consistent with previous estimates (McLean et al., 1999; Wang et al., 1999; Moore et al., 2012) . The distribution of amyloid-b in both control and Alzheimer's disease brain tissue is consistent with amyloid-b remaining in a lipid/membrane pool after cleavage, consistent with its physiochemical properties. This is demonstrated in our data with $50% of the total amyloid-b found in the Na 2 CO 3 and urea/detergent fractions. The low proportion of amyloid-b in the soluble phase indicates that there are no active transport processes of amyloid-b into the soluble phase, which agrees with previous reports of avid non-receptor mediated neuronal membrane uptake of amyloid-b (Hossain et al., 2007; Kandimalla et al., 2009) . Without active transport, we propose that amyloid-b transitions from the membrane to a weakly associated peripheral membrane and finally to a soluble protein, most likely as a complex with chaperones such as APOE (Strittmatter et al., 1993) or ApoJ/clusterin (Zlokovic et al., 1994; Wilhelmus et al., 2007) and not as a free monomer. Consistent with this distribution model of amyloid-b, we found significant correlations between the TBS, Na 2 CO 3 , urea/detergent and formic acid fractions of amyloid-b. This suggests that an exchange between the pools may exist under normal conditions. The loss of the correlations between the amyloid-b 42 peptide pools in Alzheimer's disease (Fig. 4) indicates that in the Alzheimer's disease brain, the changes likely reflect amyloid-b being trapped or lost in the fibrillary insoluble pools by deposition in plaques (Fig. 6) Patterson et al., 2015) . This may have important implications for our understanding of the synaptic toxicity of amyloid-b in Alzheimer's disease (Koffie et al., 2009; Bilousova et al., 2016) . The traditional model is that toxicity is driven by soluble amyloid-b o , which is based on the observations that the levels of soluble amyloid-b correlate with cognitive impairment and synaptic loss (McLean et al., 1999) and experimental models including cell culture, transgenic animals and organotypic electrophysiological experiments (reviewed in Benilova et al., 2012; Roberts et al., 2012; Walsh and Teplow, 2012) . However, the exchange between the soluble and membrane pools suggests that the conclusions that pertain to soluble levels of amyloid-b are equally applicable to the lipid/membrane-associated fractions. The abundance ($50-60% of total amyloid-b) of amyloid-b in the lipid/ membrane-associated fractions warrants intense study to determine its role in Alzheimer's disease. This is particularly relevant when considering the concentration of amyloid-b used in the majority of ex vivo toxicity experiments that are typically in the micromolar range. This is a concentration of 100-1000-fold more than what is observed in the soluble fraction from brain. This discrepancy may be reconciled by considering the concentration of amyloid-b in the peripheral and integral membrane compartments (Supplementary Table 2 ). Based on the amounts of amyloid-b per gram of tissue, the Na 2 CO 3 and urea/detergent fractions have amyloid-b concentrations of 0.2-1.4 mM. This matches the range of amyloid-b concentrations used in the literature to induce toxicity. When we consider that membrane-associated amyloid-b would be topologically confined, then the local concentrations at the extracellular face of the membrane could approach 30 mM. Determining the functional consequence of these high levels of amyloidb compared to the soluble phase, could account for the synaptotoxic properties of Alzheimer's disease. The literature is heavily biased by the study of only two species of amyloid-b peptide (amyloid-b 1-40 and amyloidb 1-42 ), despite the majority of the peptide originally sequenced being amyloid-b 4-42 (Masters et al., 1985) . To determine the isotype of amyloid-b, we used a combination of urea PAGE western blots that resolve amyloid-b species based on hydrophobicity (Klafki et al., 1996; McColl et al., were calculated for each biochemical fraction. The mean and standard deviation are shown; significance was determined by unpaired t-test with equal variance and Bonferroni correction indicates a P-value only 5 0.006 as significant (0.05/8). A significant difference in the 42/40 ratio is observed for the TBS fraction only. AD = Alzheimer's disease. Formic acid µg of A / g of wet weight
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Urea-detergent µg of A / g of wet weight isotype in peripheral tissues/fluids such as blood and CSF (Mehta et al., 2000; Rembach et al., 2014a) .
Correlation of amyloid-b-PET with distinct biochemical pools of amyloid-b
Amyloid-b imaging with PET is considered a reliable measure of Alzheimer's disease-related amyloid-b burden and a useful aid to the diagnosis of Alzheimer's disease (Klunk et al., 2005; Rowe and Villemagne, 2013) . We compared the level of amyloid-b in each biochemical pool with antemortem measures of amyloid-b by PET in the same frontal region. The correlation with the amyloid-b-PET signal was strongest for the urea/detergent and formic acid fractions and less so with the Na 2 CO 3 fraction. No significant correlation was observed with the TBS soluble fraction. This indicates that amyloid-b-PET is a measure of the amount of amyloid-b in the urea/detergent and formic acid fractions. This is consistent with previous data that demonstrated that 90% of the amyloid-b-PET ligand was in a highly insoluble protein-lipid complex (Matveev et al., 2014) , similar to the urea/detergent fraction analysed in this study. As the amyloid-b-PET ligand has less than 120 min to equilibrate while the image is being acquired, it is likely that the PET image is more closely related to a fraction that is in transition from the membrane to the outer surface of the amyloid-b amyloid plaque cores and perivascular amyloid-b amyloid deposits. In contrast, the low nanomolar concentration of amyloid-b in the soluble TBS fraction is most likely to be reflected in the low nano/picomolar concentration in CSF obtained by lumbar puncture (Blennow et al., 2015; Palmqvist et al., 2016) . The combination of the frontal amyloid-b-PET values and the biochemical assays of amyloid-b in the same brain region allowed us to estimate a conversion of PET signal to microgram of amyloid-b per gram of tissue (0.69 mg/0.1 SUVR). This is an important finding for therapeutic trials designed to clear amyloid-b from the brain (Karran et al., 2011) .
Estimated rates of amyloid-b accumulation
The accumulation of amyloid-b amyloid in Alzheimer's disease occurs over a period of 20-30 years . In sporadic Alzheimer's disease, amyloid-b accumulation is due to a decreased clearance of the peptide and its movement into an insoluble fibrillary fraction (Mawuenyega et al., 2010) . In this study, we show that only $5 mg of amyloid-b separates Alzheimer's disease from control cases (Table 1) . Given the known time course of amyloid-b accumulation of $20 years, and the difference in total amyloid-b between Alzheimer's disease and controls ( to accumulate 5 mg of amyloid-b in the brain over a 20-year time frame (4.8 mg/168 307 h = 28.5 ng/h). Our estimated rate of amyloid-b deposition (28 ng/h) in the brain is remarkably similar to the rate of amyloid-b 42 deposition (31.2 ng/h) into plaques estimated from human CSF measurements . These estimates indicate that a subtle 2-5% overall increase in deposition of amyloid-b is all that is required to shift from healthy control towards development of Alzheimer's disease. This may explain why the development of Alzheimer's disease takes 20 years and how small deficits in clearance efficiency modulated by genetic factors (e.g. apolipoprotein E) can lead to the disease.
